Following the release of the "Top 100 Chinese Pharmaceutical Innovation Enterprises 2026" list—where Sino Biopharm has consistently ranked in the top three for many years—the 11th PDI Pharmaceutical R&D Innovation Conference announced the 2026 Pharmaceutical R&D Strength Ranking. As a core enterprise of Sino Biopharm (1177.HK), Chia Tai Tianqing has been ranked at the forefront of the "China Pharmaceutical R&D Comprehensive Strength Ranking" and its sub-rankings, the "China Chemical Drug R&D Strength Ranking" and the "China Biopharmaceutical R&D Strength Ranking", for 11 consecutive years. 

 

 

 

 

Intensive Launch of Innovative Products, Building a Diverse Therapeutic Product Matrix

 

In recent years, Chia Tai Tianqing has continuously increased its R&D investment, with cumulative R&D expenses exceeding 18 billion RMB during the "14th Five-Year Plan" period; in 2025, annual R&D expenses surpassed 4.6 billion RMB, accounting for over 23% of the company's operating revenue. High-intensity R&D investment is continuously being transformed into clinical value, driving the company to form a more complete innovative product matrix in key therapeutic areas such as oncology, liver disease/cardiovascular metabolism, respiratory/autoimmune, and surgery/analgesia. 

 

From 2025 to the present, several innovative products independently developed or strategically partnered by Chia Tai Tianqing have been approved for marketing, truly achieving clinical accessibility:

 

● Rovadicitinib Tablets (Anxu^®): A global first-in-class (FIC) dual-target Janus kinase (JAK)/Rho-associated coiled-coil containing protein kinase (ROCK) small molecule inhibitor, providing a new treatment option for patients with intermediate- or high-risk myelofibrosis; 

 

● Culmerciclib Capsules (Saitanxin^®): The world's first Cyclin-dependent kinase (CDK) 2/4/6 inhibitor, with both first- and second-line treatment indications for advanced breast cancer approved; 

 

● Zongertinib Tablets (Hernexeos^®): The world's first oral targeted drug for the treatment of HER2-mutant advanced non-small cell lung cancer; 

 

● Recombinant Human Coagulation Factor VIIa N01 for Injection (Anqixin^®): The first domestically produced recombinant human coagulation factor VIIa biologic, achieving high-quality domestic substitution; 

 

● Naldemedine Tosilate Tablets (SYMPROIC^®): The world's first oral selective peripheral μ-opiate receptor antagonist, which fundamentally reverses opiate-induced constipation (OIC); 

 

● Peceleganan Spray (Puyike^®): A global first-in-class (FIC) Ganan-class anti-infective drug for the treatment of secondary wound infections in burns. 

 

As the company's "ace card" in the anti-tumor field, Anlotinib Hydrochloride Capsules (Fukewei^®) in combination with Benmelstobart Injection (Andewei^®) or Penpulimab Injection (Annike^®) successively added 3 first-line indications in 2025. This powerful combination continues to solidify the domestic foundation in anti-tumor therapy. 

 

In addition, the New Drug Applications for the global first-in-class (FIC) new drug Bepirovirsen, from the exclusive strategic cooperation with GlaxoSmithKline (GSK); the CLDN18.2 ADC Tecotabart Vedotin for Injection, independently developed by LaNova Medicines and filed by Shanghai Chia Tai Tianqing; and the first domestic CD3/Epithelial cell adhesion molecule (EpCAM) bispecific antibody M701 have all been accepted by the CDE, expected to bring new treatment options for first-line patients with urgent therapeutic needs. 

 

Full-Chain Technology Platforms as Foundation, International Cooperation Promotes Medication Accessibility

 

 

Behind the continuous innovation is the support of Chia Tai Tianqing's full-chain technology platform, from drug discovery to industrialization. Focusing on areas such as chemical drugs, biologics, innovative formulations, clinical medical research, and key industrialization technologies, the company has built multiple R&D and translational platforms, including AI drug discovery, oral Proteolysis-targeting chimera (PROTAC), siRNA innovative drugs, advanced antibodies, ADC, biologic combination products, inhalation formulations, and transdermal formulations, forming a systemic capability covering early discovery, clinical development, large-scale production, and commercialization. Keeping pace with the wave of AI development, the company is deeply exploring the entire business chain, including AI-assisted drug screening, clinical trial research, intelligent production, and corporate management, with its digital transformation entering a stage of rapid advancement. 

 

Facing the new landscape of the global pharmaceutical industry, Chia Tai Tianqing continues to promote open cooperation, actively integrating local Chinese innovation resources, and establishing deep cooperative relationships with domestic and international enterprises and research institutions. Since 2025, the company's strategic collaborations with multinational pharmaceutical companies such as Boehringer Ingelheim and Shionogi have continued to advance; an exclusive licensing agreement was reached with Sanofi for the independently developed Rovadicitinib tablets; and the collaboration with GSK on Bepirovirsen is also expected to bring new breakthroughs in the field of hepatitis B treatment. 

 

Chia Tai Tianqing will continue to focus on major clinical needs, adhere to high-quality R&D investment and systematic innovation construction, and accelerate the process of bringing more innovative drugs with differentiated clinical value to patients and to the world, continuously playing a leading role in the international development of China's pharmaceutical innovation.